Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Pablo Olivera, Silvio Danese & Laurent Peyrin-Biroulet. (2017) JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology 13:7, pages 693-703.
Read now
Read now
Articles from other publishers (20)
Xue Yuan, Yong Chen, Minghai Tang, Yuhan Wei, Mingsong Shi, Yingxue Yang, Yanting Zhou, Tao Yang, Jiang Liu, Kongjun Liu, Dexin Deng, Chufeng Zhang & Lijuan Chen. (2022) Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs). Journal of Medicinal Chemistry 65:13, pages 9312-9327.
Crossref
Crossref
Elleni J Pippis & Bruce R Yacyshyn. (2021) Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflammatory Bowel Diseases 27:10, pages 1674-1683.
Crossref
Crossref
Xuewen Wang, Shuhua Chen, Hong Xiang, Ziwei Liang & Hongwei Lu. (2021) Role of sphingosine‐1‐phosphate receptors in vascular injury of inflammatory bowel disease. Journal of Cellular and Molecular Medicine 25:6, pages 2740-2749.
Crossref
Crossref
Xiao-Ling Zhou, Juan Yang, Xian-Jun Qu, Jian Meng, Rong-Rong Miao & Shu-Xiang Cui. (2020) M10, a Myricetin-3-O-b-D-Lactose Sodium Salt, Prevents Ulcerative Colitis Through Inhibiting Necroptosis in Mice. Frontiers in Pharmacology 11.
Crossref
Crossref
Kristi A. Leonard, Lisa A. Madge, Paul J. Krawczuk, Aihua Wang, Kevin D. Kreutter, Genesis M. Bacani, Wenying Chai, Russell C. Smith, Mark S. Tichenor, Michael C. Harris, Ravi Malaviya, Mark Seierstad, Marguerite E. Johnson, Jennifer D. Venable, Suzie Kim, Gavin C. Hirst, Ashok S. Mathur, Tadimeti S. Rao, James P. Edwards, Michele C. Rizzolio & Tatiana Koudriakova. (2020) Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry 63:6, pages 2915-2929.
Crossref
Crossref
Mirabella Zhao, Flemming Bendtsen, Andreas Munk Petersen, Lone Larsen, Anders Dige, Christian Hvas, Jakob Benedict Seidelin & Johan Burisch. (2020) Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy—the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open 10:2, pages e035756.
Crossref
Crossref
Meiling SunYangyang ZhouYang ShiBingrong Liu. (2019) Effect of the Sphingosine Kinase 1 Selective Inhibitor, PF543 on Dextran Sodium Sulfate-Induced Colitis in Mice. DNA and Cell Biology 38:11, pages 1338-1345.
Crossref
Crossref
Ritesh M. Pabari, Clara Mattu, Sailesh Partheeban, Aqeel Almarhoon, Monica Boffito, Gianluca Ciardelli & Zebunnissa Ramtoola. (2019) Novel polyurethane-based nanoparticles of infliximab to reduce inflammation in an in-vitro intestinal epithelial barrier model. International Journal of Pharmaceutics 565, pages 533-542.
Crossref
Crossref
Julián Panés & Javier P. Gisbert. (2019) Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 42:6, pages 403-412.
Crossref
Crossref
Julián Panés & Javier P. Gisbert. (2019) Efficacy of tofacitinib treatment in ulcerative colitis. Gastroenterología y Hepatología (English Edition) 42:6, pages 403-412.
Crossref
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2019) Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina Clínica 152:9, pages 353-360.
Crossref
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2019) JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina Clínica (English Edition) 152:9, pages 353-360.
Crossref
Crossref
Marco Gentili, Simona Ronchetti, Erika Ricci, Rosanna Di Paola, Enrico Gugliandolo, Salvatore Cuzzocrea, Oxana Bereshchenko, Graziella Migliorati & Carlo Riccardi. (2019) Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease. Pharmacological Research 141, pages 21-31.
Crossref
Crossref
Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum & Ole Haagen Nielsen. (2018) Targeting JAK-STAT signal transduction in IBD. Pharmacology & Therapeutics 192, pages 100-111.
Crossref
Crossref
Seyed Tayebati. (2018) Phospholipid and Lipid Derivatives as Potential Neuroprotective Compounds. Molecules 23:9, pages 2257.
Crossref
Crossref
Fernando Velayos. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
303
313
.
Grainne Holleran, Loris Lopetuso, Valentina Petito, Cristina Graziani, Gianluca Ianiro, Deirdre McNamara, Antonio Gasbarrini & Franco Scaldaferri. (2017) The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. International Journal of Molecular Sciences 18:10, pages 2020.
Crossref
Crossref
Laurent Peyrin-Biroulet, Ronald Christopher, Dominic Behan & Cheryl Lassen. (2017) Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmunity Reviews 16:5, pages 495-503.
Crossref
Crossref
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni & Daniella M. Schwartz. (2017) JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:5, pages 521-546.
Crossref
Crossref
Pablo Olivera, Silvio Danese & Laurent Peyrin-Biroulet. (2017) Next generation of small molecules in inflammatory bowel disease. Gut 66:2, pages 199-209.
Crossref
Crossref